AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39760815
Drug: AL2846 combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 combined with gemcitabine (90 mg and 120 mg)
Trial: 39760983
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% applied twice daily for 4 weeks, then as needed up to 52 weeks
Trial: 39761005
Drug: hSAP (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hSAP (12.5 μg/g)
Trial: 39761829
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg daily
Trial: 39762092
Drug: Patch ECG
RxNorm normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch ECG (ECG247 Smart Heart Sensor)
Trial: 39762098
Drug: 300 mg omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg omalizumab administered subcutaneously every 4 weeks (Q4W) for 36 weeks
Trial: 39762098
Drug: 300 mg omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg omalizumab administered subcutaneously every 6 weeks (Q6W) for 36 weeks
Trial: 39762098
Drug: Blood samples,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples, Weekly Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire, Dermatology Life Quality Index
Trial: 39762113
Drug: EIMG (Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EIMG (Exercise is Medicine Greenville) intervention with a standardised instructional video and a 12-week evidence-informed physical activity programme.
Trial: 39762248
Drug: AG-270/S095033 (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-270/S095033 (oral, potent, reversible inhibitor of MAT2A) administered once daily (QD) or twice daily (BID) in 28-day cycles.
Trial: 39762418
Drug: neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group A)
Trial: 39762418
Drug: neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group B)
Trial: 39762419
Drug: Glecirasib (JAB-21822)
RxNorm normalized name: Glecirasib
DrugBank: Glecirasib (DB18744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecirasib (JAB-21822) administered orally at 800 mg daily
Trial: 39762422
Drug: Autogene cevumeran
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogene cevumeran monotherapy
Trial: 39762740
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg orally disintegrating tablet
Trial: 39762879
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid vaginal gel applied for 12 days
Trial: 39762879
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole 500 mg twice daily for seven days
Trial: 39763581
Drug: Intravenous levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous levocarnitine (20 mg/kg body weight, infused over 2-3 min after each hemodialysis session for 24 weeks)
Trial: 39763581
Drug: Oral levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levocarnitine (500 mg three times daily for 24 weeks)
Trial: 39763591
Drug: GV (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV (gel vehicle, placebo)
Trial: 39764100
Drug: Preoperative eribulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative eribulin (1.1 mg/m² for three 21-day cycles)
Trial: 39764289
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg every 4 weeks on top of standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Trial: 39764289
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Trial: 39764289
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg every 4 weeks
Trial: 39764567
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy (PT) - two 25 mg doses administered orally with psychological support
Trial: 39764567
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment (ET) - 6-week course with daily doses of 10 mg for three weeks and 20 mg for the subsequent three weeks plus matched psychological support
Trial: 39765128
Drug: Pulmonary hypertension
RxNorm normalized name: Alyq 20 MG Pulmonary Hypertension Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary hypertension treatments
Trial: 39767014
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement consisting of 400 mg of a standardized extract of the persimmon fruit
Trial: 39768420
Drug: Dulaglutide and
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide and Dapagliflozin combination
Trial: 39768420
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitor (DPP-4i)
Trial: 39769389
Drug: CBA-1205 (afucosylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBA-1205 (afucosylated humanized antibody against DLK1)
Trial: 39769389
Drug: CBA-1205 in
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBA-1205 in combination with lenvatinib
Trial: 39770444
Drug: Δ8-THCV after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ8-THCV after oral administration
Trial: 39770949
Drug: Carnosine 2
RxNorm normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine 2 g/day for 14 weeks
Trial: 39771516
Drug: Novel Lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel Lipid Formulation of Cannabidiol (CBD)
Trial: 39771516
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard formulation of CBD)
Trial: 39772364
Drug: Gallium-68-labeled fibroblast
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallium-68-labeled fibroblast activation protein inhibitor
Trial: 39772606
Drug: Intraarterial tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial tenecteplase up to 4.5 mg
Trial: 39772650
Drug: Intravenous fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosfomycin
Trial: 39772709
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (RIC); unilateral upper limb; cuff pressure 200 mm Hg, twice daily for 7 days
Trial: 39773014
Drug: Short-acting β-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β-agonist (SABA) overuse
Trial: 39773112
Drug: PTSD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTSD treatment strategies
Trial: 39773121
Drug: Molecular profiling
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular profiling techniques including DNA, RNA, and T-cell receptor sequencing on SBA tissue samples.
Trial: 39773406
Drug: SAC therapists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAC therapists providing effective treatment tools
Trial: 39773433
Drug: PA+Dex (Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA+Dex (Physical Activity + Dexamethasone 4 mg twice daily for the first 7 days)
Trial: 39773460
Drug: GoldiCare intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GoldiCare intervention (redistributing weekly workloads)
Trial: 39773562
Drug: Durvalumab (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1,500 mg, intravenously, every four weeks for 26 cycles max) plus tremelimumab (75 mg, intravenously, every four weeks for 4 cycles max) plus metronomic oral vinorelbine (40 mg, every three weeks)
Trial: 39773564
Drug: VB10.16 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VB10.16 (3 mg every 3 weeks for 12 weeks, then every 6 weeks) combined with atezolizumab (1,200 mg every 3 weeks for 48 weeks)
Trial: 39773801
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (oral follow-up advice and a baseline follow-up card)
Trial: 39773831
Drug: Warfarin (international
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (international normalised ratio goal of 2.0-2.5)
Trial: 39773848
Drug: MOON (serious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOON (serious video game) plus standard pharmacological treatment
Trial: 39773848
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pharmacological treatment only)
Trial: 39773886
Drug: Aspirin-ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin-ticagrelor
Trial: 39773950
Drug: Patch-based PSG
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patch-based PSG
Trial: 39774313
Drug: Xalnesiran 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalnesiran 100 mg (group 1)
Trial: 39774313
Drug: Xalnesiran 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalnesiran 200 mg (group 2)
Trial: 39774313
Drug: Xalnesiran 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalnesiran 200 mg + ruzotolimod 150 mg (group 3)
Trial: 39774313
Drug: Xalnesiran 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalnesiran 200 mg + pegylated interferon alfa-2a 180 μg (group 4)
Trial: 39774855
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C treatment
Trial: 39774967
Drug: RBI-4000 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBI-4000 single administration at 1 microgram
Trial: 39774967
Drug: RBI-4000 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBI-4000 single administration at 10 microgram
Trial: 39774967
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of RBI-4000
Trial: 39775041
Drug: Optimized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized oral antiparkinsonian therapy
Trial: 39775042
Drug: Suraxavir marboxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suraxavir marboxil (40 mg)
Trial: 39775195
Drug: Morning bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning bright light therapy (MBLT); 60-min duration; daily over 28-day duration
Trial: 39775195
Drug: Sham: deactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham: deactivated negative ion generator; 60-min duration; daily over 28-day duration
Trial: 39775226
Drug: Topical therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy, methotrexate, adalimumab, secukinumab, guselkumab
Trial: 39775763
Drug: Gilteritinib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gilteritinib maintenance therapy
Trial: 39775808
Drug: mHealth-CR (commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth-CR (commercially available software on a tablet, remote monitoring, weekly exercise therapist calls for 3 months)
Trial: 39775812
Drug: anti-CD22 CAR
RxNorm normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD22 CAR T-cell (CAR22) therapy
Trial: 39775962
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil inhalation for 20 minutes prior to bed for 5 consecutive days
Trial: 39775962
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution inhalation for 20 minutes prior to bed for 5 consecutive days
Trial: 39775962
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil inhalation